Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Aggressive Non-Hodgkin Lymphoma”

303 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 303 results

Early research (Phase 1)WithdrawnNCT02875002
What this trial is testing

Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas

Who this might be right for
Relapsed and Refractory Aggressive B- and T-cell LymphomasLymphoma
Yale University
Large-scale testing (Phase 3)Study completedNCT03366272
What this trial is testing

Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients

Who this might be right for
Lymphoma, Non-Hodgkin
Universität des Saarlandes 348
Testing effectiveness (Phase 2)WithdrawnNCT04882163
What this trial is testing

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Who this might be right for
Lymphoma, B-Cell
Celgene
Testing effectiveness (Phase 2)Ended earlyNCT00664144
What this trial is testing

Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma

Who this might be right for
Hyperuricemia
Sanofi 33
Testing effectiveness (Phase 2)Active Not RecruitingNCT05025800
What this trial is testing

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Who this might be right for
Aggressive B-Cell Non-Hodgkin LymphomaAnn Arbor Stage III Grade 2 Follicular LymphomaAnn Arbor Stage III Grade 3 Follicular Lymphoma+17 more
M.D. Anderson Cancer Center 47
Large-scale testing (Phase 3)Study completedNCT00088530
What this trial is testing

BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Lymphoma, Non-Hodgkin
CTI BioPharma 140
Testing effectiveness (Phase 2)Looking for participantsNCT05260957
What this trial is testing

CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

Who this might be right for
Refractory Non-Hodgkin LymphomaRelapsed Non Hodgkin LymphomaAggressive Non-Hodgkin Lymphoma
Lazaros Lekakis 22
Large-scale testing (Phase 3)Study completedNCT00866203
What this trial is testing

HDS Plus PBPC Transplant Vs 4 More Courses of FrontLine Therapy in Pts With Aggressive NHL in PR After Induction Therapy

Who this might be right for
High-Grade Lymphomas
Gruppo Italiano Studio Linfomi 441
Testing effectiveness (Phase 2)Looking for participantsNCT06238648
What this trial is testing

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

Who this might be right for
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedPrimary Mediastinal Large B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Academic and Community Cancer Research United 120
Early research (Phase 1)Ended earlyNCT00671112
What this trial is testing

Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma

Who this might be right for
714leukemiaLymphoma
Brian Hill, MD, PhD 30
Testing effectiveness (Phase 2)UnknownNCT02678299
What this trial is testing

Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study

Who this might be right for
Malignant Lymphoma
University of Aarhus 60
Testing effectiveness (Phase 2)Looking for participantsNCT03938987
What this trial is testing

Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Relapsed Non Hodgkin LymphomaRelapsed Adult ALLRelapsed Pediatric ALL
University of Alberta 63
Early research (Phase 1)Active Not RecruitingNCT04231877
What this trial is testing

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Who this might be right for
Aggressive Non-Hodgkin LymphomaALK-Positive Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise Specified+6 more
University of Washington 56
Testing effectiveness (Phase 2)Active Not RecruitingNCT04531046
What this trial is testing

Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation

Who this might be right for
B-Cell Lymphoma RefractoryB-cell Lymphoma Recurrent
The Lymphoma Academic Research Organisation 62
Testing effectiveness (Phase 2)UnknownNCT03837873
What this trial is testing

DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

Who this might be right for
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaTransformed Lymphoma
Institute of Hematology & Blood Diseases Hospital, China 118
Testing effectiveness (Phase 2)Active Not RecruitingNCT03625037
What this trial is testing

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

Who this might be right for
DLBCLHigh-grade B-cell Lymphoma (HGBCL)Primary Mediastinal Large B-cell Lymphoma (PMBCL)+6 more
Genmab 666
Early research (Phase 1)WithdrawnNCT04372641
What this trial is testing

Testing the Safety of CB-5339 in Patients With Cancer

Who this might be right for
Aggressive Non-Hodgkin LymphomaIndolent Non-Hodgkin LymphomaLocally Advanced Malignant Solid Neoplasm+1 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT00607854
What this trial is testing

Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)

Who this might be right for
Diffuse Large B-Cell LymphomaMantle Cell Lymphoma
University Hospital, Bordeaux 31
Testing effectiveness (Phase 2)Study completedNCT00081861
What this trial is testing

Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center 13
Testing effectiveness (Phase 2)Active Not RecruitingNCT03749018
What this trial is testing

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Aggressive Non-Hodgkin LymphomaAnn Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaAnn Arbor Stage II B-Cell Non-Hodgkin Lymphoma+11 more
David Bond, MD 30
Next Page